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Despite important progress in understanding the molecular factors underlying the development of cancer and the improvement in
response rates with new drugs, long-term survival is still disappointing for most common solid tumours. This might be because very
little of the modest gain for patients is the result of the new compounds discovered and marketed recently. An assessment of the
regulatory agencies’ performance may suggest improvements. The present analysis summarizes and evaluates the type of studies and
end points used by the EMEA to approve new anticancer drugs, and discusses the application of current regulations. This report is
based on the information available on the EMEA web site. We identified current regulatory requirements for anticancer drugs
promulgated by the agency and retrieved them in the relevant directory; information about empirical evidence supporting the
approval of drugs for solid cancers through the centralised procedure were retrieved from the European Public Assessment Report
(EPAR). We surveyed documents for drug applications and later extensions from January 1995, when EMEA was set up, to
December 2004. We identified 14 anticancer drugs for 27 different indications (14 new applications and 13 extensions). Overall, 48
clinical studies were used as the basis for approval; randomised comparative (clinical) trial (RCT) and Response Rate were the study
design and end points most frequently adopted (respectively, 25 out of 48 and 30 out of 48). In 13 cases, the EPAR explicitly
reported differences between arms in terms of survival: the range was 0–3.7 months, and the mean and median differences were 1.5
and 1.2 months. The majority of studies (13 out of 27, 48%) involved the evaluation of complete and/or partial tumour responses,
with regard to the end points supporting the 27 indications. Despite the recommendations of the current EMEA guidance
documents, new anticancer agents are still often approved on the basis of small single arm trials that do not allow any assessment of
an ‘acceptable and extensively documented toxicity profile’ and of end points such as response rate, time to progression or
progression-free survival which at best can be considered indicators of anticancer activity and are not ‘justified surrogate markers for
clinical benefit’. Anticipating an earlier than ideal point along the drug approval path and the use of not fully validated surrogate end
points in nonrandomised trials looks like a dangerous shortcut that might jeopardise consumers’ health, leading to unsafe and
ineffective drugs being marketed and prescribed. The present Note for Guidance for new anticancer agents needs revising. Drugs
must be rapidly released for patients who need them but not be at the expense of adequate knowledge about the real benefit of the
drugs.
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Mankind has never had so much knowledge and understanding of
cancer as at present and this has generated a large number of
approaches for developing new anticancer agents. However,
despite important progress in understanding the molecular factors
underlying the development of cancer and the improvement in
response rates with new drugs, long-term survival is still
disappointing for most common solid tumours (Berrino et al,
1999; Coleman, 1999; Levi et al, 2000). Most of the improvement in
terms of age-standardised mortality in the EU is probably
attributable to primary and secondary prevention, but survival
gains with pharmacological treatments for common advanced/
metastatic cancers are still measured in months, not years.
Several factors explain this gap between the explosion of
information from basic (preclinical) research and its relatively
poor yield for patients (Lee et al, 2000; Bast et al, 2001; Nathan,
2002; Apolone, 2003; Lenfant, 2003; Crowley et al, 2004). One
simple explanation is that very little of the modest gain is actually
the result of new compounds discovered and marketed recently.
Doubts have indeed been raised about the added value of the new
‘targeted’ molecules compared to the classic and less-expensive
anticancer drugs (Garattini and Bertele’, 2002; Leaf, 2003), also in
the framework of drug approvals (Roberts and Chabner, 2004).
Although much of the development of anticancer drugs
continues after the regulatory agencies’ approval, the US and EU
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sagencies, FDA and EMEA, play a major role in improving public
health as they fall between clinical trials and (public) health care
and are thus responsible for the first scientific evaluation of the
quality, safety and efficacy of new drugs. A look at the regulatory
agencies’ performance suggests some improvements. The FDA
itself has recently reported its experience with oncology drugs
(Johnson et al, 2003; Dagher et al, 2004).
The present analysis summarises and evaluates the types of
studies and end points used by the EMEA over the last 10 years to
approve new anticancer drugs through the centralised procedure,
and discusses the application of the current regulations.
MATERIAL AND METHODS
This report is based on the information available on the EMEA web
site. Current regulatory requirements for anticancer drugs
promulgated by the Agency (Note for Guidance and other
documents) were identified and retrieved in the relevant directory
(http://www.emea.eu.int/). Information about empirical evidence
supporting the approval of anticancer drugs was retrieved from the
European Public Assessment Report (EPAR) (http://www.e-
mea.eu.int/index/indexh1.htm), a list of documents available in
the public domain that describes the steps, reasons, scientific
summary, technical documents and commitment for approval of a
given drug, and the summary of product characteristics. Docu-
ments were surveyed for new applications and later extensions
from January 1995, when EMEA was set up, to December 2004.
This evaluation only includes anticancer drugs for solid cancers
approved by the EMEA through the centralised procedure,
including hormone treatments but excluding drugs for haemato-
logical cancers, such as leukaemia, lymphomas and multiple
myeloma, and supportive therapies such as bisphosphonates.
We collected the following information: name of the active
substance, year of approval, indication, design of the pivotal trials,
number of patients in each trial, primary and secondary end points
supporting the approval and difference in survival between arms,
when available. We used the following definitions: a new indication
was the first approval for a given drug, and later approvals were
considered extensions; the trial design was classified as a
randomised comparative (clinical) trial (RCT), or randomised
noncomparative (phase II) trial (RNCT) or a single-arm trial (SAT)
or other; the number of patients was generally the number
included in the trial; the primary efficacy end points were those
reported in the EPAR and were classified as survival, time to
progression/progression-free survival (TTP/PFS) or response rate.
RESULTS
Current regulatory guidance for anticancer drugs
According to the guideline documents, phase III randomised
comparative trials are generally required for marketing authorisa-
tion. The minimum requirement is normally one controlled trial
with statistically compelling and clinically relevant results. As there
is general demand for replication of scientific results, it is usually
recommended to plan more than one study in the phase III
programme. Directive 75/318/EEC provides for the possibility of
granting marketing authorisation under exceptional circum-
stances, when in the present state of scientific knowledge,
comprehensive information on the efficacy and safety under
normal conditions of use cannot be provided.
In this situation, should an applicant consider that phase II
studies have unequivocally established outstanding benefits of the
new agent for the target patients, the applicant must fully justify
this position before authorisation can be granted. In addition, a
further trial programme must be agreed, together with any other
experimental studies deemed necessary on the basis of adverse
drug reactions. The CPMP Note for Guidance ‘Evaluation of
anticancer medicinal products in man’ (CPMP/EWP/205/95 rev.2,
19 September 2002) presents guidelines on the requirements for
authorisation for all anticancer drugs, particularly cytotoxic/
cytostatic agents, and is intended to assist applicants in regular
and exceptional circumstances (http://www.emea.eu.int/). It de-
fines phase III trials as (therapeutic confirmatory) disease-oriented
trials that seek to confirm the activity of the product seen in phase
II (therapeutic exploratory) studies in the claimed indication, and
specifies that a phase III clinical trial is comparative in nature and
should allow a full evaluation of the active agent selected at the end
of phase II. When the comparator is established, noninferiority
trials are possible. Where this is not the case, a superiority trial is
generally required.
Appropriate efficacy end points include progression-free/
recurrence-free/relapse-free survival, overall survival, response
rate and symptom control/quality of life. The primary end point
should be selected a priori and justified on clinical relevance and
methodological considerations. Randomised comparative (clinical)
trial are normally always required, noncomparative studies being
considered acceptable only in the case of pretreated patients when
no established regimens do exist. This applies in very specific
circumstances that are summarised in Box 1.
Data supporting approval of anticancer drugs
We identified 14 anticancer drugs for 27 different indications (14
new applications and 13 extensions). Table 1 shows the main
characteristics of each drug approved from 1995 to 2004, according
to the indications. In general, a drug was approved on the basis of
results from phase II or phase III studies. In one case only,
approval was granted without empirical data, on the basis of a
bibliographic review of nonclinical and clinical data (mitotane, for
adrenal cortical carcinoma).
Often a drug was first approved on the basis of preliminary
evidence from RNCT. Subsequently, new data from comparative
studies made it possible to define the initial indication better or to
extend the use of the drug to other diseases. For example,
docetaxel was approved in 1995 under exceptional circumstances
as single agent for the treatment of advanced/metastatic breast
cancer, after failure of cytotoxic therapy that included an
anthracycline or an alkylating agent. No data from phase III RCTs
were submitted. In 1997, data from two RCTs were available, and
Box 1 CPMP guidance on regulatory requirements for anticancer agents within applications under exceptional circumstances ‘Evaluation of anticancer
medicinal products in man’ ‘CPMP/EWP/205/95 rev.2, 19 September 2002’
Noncomparator studies may be acceptable in this subgroup (previously treated patients – no existing established regimen) only in the following circumstances:
(a) Proven outstanding anticancer activity (relative to the given clinical situation and based on response rate and duration of response) in patients strictly defined as
resistant to relevant first-line therapies and
(b) The new agent has an acceptable and extensively documented toxicity profile and
(c) Tumour response is a justified surrogate marker for clinical benefit and
(d) The overall results indicate a positive risk/benefit assessment for this treatment in this clinically identifiable group of patients
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sthe indication was confirmed and extended to two other clinical
situations in advanced breast cancer patients. Eventually, in 1999,
docetaxel was also approved for locally advanced or metastatic
non-small-cell lung cancer on the basis of several RCTs. All
together, docetaxel has five different indications, three in specific
clinical situations for advanced breast cancer and two for advanced
or metastatic non-small-cell lung cancer.
Overall, 48 clinical trials were used for approval of the 27
indications; RCT and response rate were the study design and the
end points most frequently adopted (25 out of 48, and 30 out of
48). In 13 cases, the EPAR explicitly reported the differences
between arms in terms of survival (reported as primary or
secondary end points): the range was 0–3.7 months, and the mean
and median differences were 1.5 and 1.2 months (Table 2). The
mean numbers of patients recruited were, respectively 92, 222 and
406 for SAT, RNCT and RCT.
Table 3 shows the study design and the type of primary end
point of the main studies supporting the 27 indications: phase III
RCTs were available for half the indications, followed by SAT for
30% and RNCT for 14%; approval was based on at least two RCTs
only for five products. As regard the end points supporting the 27
indications, the majority of cases (13 out of 27, 48%) involved
evaluation of complete and/or partial tumour responses (Table 4).
Time to TTP or PFS was next, while overall survival was available
for only two indications There was no substantial difference in the
trial design and end points between the first approval and the
extension (data not reported).
DISCUSSION
Despite the recommendations in the current EMEA guidance
documents, the approval of new anticancer agents is often still
based on small SAT that do not allow the evaluation of an
‘acceptable and extensively documented toxicity profile’, or on end
points such as response rate, TTP or PFS which at best can be
considered indicators of anticancer activity and not ‘justified
surrogate markers for clinical benefit’. In only one case at least two
RCT were available, and tumour shrinkage did not translate most
of the time into significant survival benefit, usually reported as a
secondary end point. In only one case, according to the infor-
mation reported in the EPAR for this series of cases, approval was
formally granted under the ‘exceptional circumstances’ condition.
It is beyond the scope of this paper to discuss the degree of
innovation for new drugs and/or to make a cost analysis, as it has
already been pointed out that the approval of most new anticancer
drugs by EMEA offers no substantial advantages and puts further
burdens on national health services (Garattini and Bertele’, 2002).
The present findings raise two issues: the general framework of
anticancer drug approval, regulatory tools, recommendations,
directives, etc. and specific ways to improve the development and
evaluation of these drugs (clinical trial design).
Table 1 Anticancer drugs approved by EMEA from January 1995 to December 2004
Drug Year Indication Trial design No. of patients Primary end points
Docetaxel
a 1995 ABC, second line, monotherapy 6 SAT 228 RR
Topotecan 1996 AOC, second line RCT 235 RR
Toremifene 1996 ABC, first line, postmenopausal 3 RCT 648, 415, 463 RR, RR, RR
Doxorubicin pegylated
b 1996 AIDS – Kaposi SAT 247 RR
SAT 137 RR
Docetaxel 1997 ABC, second line, with capecitabine RCT 429 TTP
ABC, first line, with doxorubicin RCT 477 TTP
Temozolide 1998 GBM, refractory RCT, SAT 225, 138 PFS, PFS
Anaplastic astrocytoma, first line SAT 162 PFS
Tasonermin 1999 Limbs sarcoma 4 SAT 39,23,23,103 RR, RR, RR, RR
Paclitaxel 1999 AIDS, Kaposi, second line SAT 107 RR
Docetaxel 1999 A-NSCLC, second line 3 RCT NA, NA, NA OS, OS, OS
A-NSCLC, first line with cis-platinum RCT 1220 OS
Doxorubicin pegylated 2000 AOC, second line RCT 474 TTP
Doxorubicin pegylated 2000 ABC, first line, when A nonindicated 2 RCT 509, 301 PFS, PFS
Paclitaxel 2000 ABC, second line or when A nonindicated NC-RCT 312 TTP
Paclitaxel 2000 ABC, second line NC-RCT 120 PFS
Trastuzumab 2000 ABC, first line in combination with paclitaxel, when A nonindicated RCT 469 TTP
ABC, second line, single agent SAT 222 RR
Altretinoin 2000 AIDS-Kaposi, after antiretroviral therapy RCT 238 RR
Capecitabine 2000 A-CRC 2 RCT 605, 602 RR, RR
Capecitabine 2000 ABC, second line with docetaxel RCT 511 TTP
ABC, second line, single agent when A nonindicated SAT 135 RR
Fulvestrand 2001 ABC, postmenopausal, second line 2 RCT 541, 473 TTP, TTP
Imatinib 2002 Adult GIST NC-RCT 117 RR
Cetuximab 2004 A-CRC, second line, in combination with irinotecan NC-RCT, 2 SAT 329, 138, 57 RR, RR, RR
Mitotane 2004 Adrenal cortical carcinoma Review Review —
ABC¼advanced breast cancer; AOC¼advanced ovarian cancer; GBM¼gliobastoma multiforme; A-CRC¼advanced colorectal cancer; A-NSCLC¼advanced non-small-cell
lung cancer; GIST¼gastrointestinal stromal tumour; A¼anthracycline; RCT¼randomised clinical trial; SAT¼single-arm trial; NC-RCT¼noncomparative RCT; OS¼overall
survival; TTP¼time to progression; PFS¼progression-free survival; RR¼response rate; NA¼not available.
aDocetaxel was first approved under exceptional circumstances on
the basis of six pooled SAT, for a total of 228 cases. Later, in 1997, full approval was granted on the basis of two RCT, with 326 and 392 patients and RR as supporting end point.
bDoxorubicin pegylated was first approved on the basis of SAT. Later, full approval was granted on the basis of two RCT, with 258 and 241 patients and with therapeutic
response and response rate, respectively, as supporting end points.
Table 2 Evaluation of anticancer drugs by EMEA from 1995 to 2004:









RCT 25 Survival 4 Range 0–3.7 months
SAT 19 Resp. rate 30 Mean 1.5 (months)
NC-RCT 4 TTP/PFS 14 Median 1.2 (months)
RCT¼randomised clinical trial; SAT¼single-arm trial; NC-RCT¼noncomparative
RCT; TTP¼time to progression; PFS¼progression-free survival.
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sThe FDA recently reported that end points other than survival
were the basis for approval of most (68%) oncology drug
marketing applications following regular approval, and for all
the applications following the accelerated approval procedure. In
addition, 25 out of 71 (35%) drugs were granted an application
without an RCT (Johnson et al, 2003; Dagher et al, 2004). The
EMEA, established in 1995, has less formal regulatory tools to
differentiate between regular and special/accelerated approval, and
specific situations are treated case by case. In general, a distinction
is made for anticancer drugs when no established treatment exists:
in this case, an SAT may be the basis for approval. EMEA recently
published a report on its 10-year experience in oncology (Chapelin
et al, 2004) evaluating the study design and end points used;
although details are not yet available, findings are very similar to
those reported in this paper for solid tumours.
Despite these formal differences between agencies, the output is
similar. Pharmaceutical companies, under the pressure of in-
vestors, test their new molecules on human beings at the earliest
possible point in order to obtain quick approval, without fully
knowing the true mechanism by which these new drugs exert their
clinical action. Often strange and specific subsamples of progres-
sing or refractory patients are selected to obtain the status of
‘accelerated approval’ or ‘under exceptional circumstances’, using
the simplest possible study design. This means that most candidate
anticancer drugs are eventually marketed on the basis of little firm
evidence. The tendency to anticipate an earlier than ideal point
along the drug approval path, and the use of not fully validated
surrogate end points in nonrandomised studies can be considered
either an important step towards a new way of protecting public
health by ensuring that beneficial drugs are made available as
quickly as possible, or a dangerous shortcut that might jeopardise
consumers’ health, allowing unsafe and ineffective drugs to be
marketed and prescribed (Castro, 2002; Horton, 2004; Psaty et al,
2004).
Although pharmacological treatment is only part of the care of
cancer patients, the use of drugs in each stage of the disease
(neoadjuvant, adjuvant, advanced, metastatic and terminal) is the
hub of recommended approaches, and a lack of evidence about
their real benefit/risk ratio may lead to overestimation of the role
of drugs in the cure or control of the disease and consequently to
overtreatment, high costs and poor outcomes. On the other hand,
though it is generally accepted that a complete dossier would be
desirable, sometimes confirmative phase III studies are hard to
arrange for ethical or feasibility reasons and most patients with
advanced disease cannot wait for the full approval, by which time
they would probably be dead. This dilemma may be partially
solved by involving patients’ organisations so cancer patients are
represented in the EMEA evaluation process to help identify fast-
track designation and by starting information and communication
initiatives at each national level to prepare patients to take the risk
of a partially proven therapy.
In addition to what has already been suggested to improve the
policy of regulatory systems, in both the USA (Leaf, 2003; Roberts
and Chabner, 2004) and EU (McVie, 2002; Garattini and Bertele’,
2002; Redmond, 2004), current guidance documents (Note for
Guidance, NfG) need to be modified in order to balance the
pharmaceutical companies’ aims with the public health systems’
mission, also in the light of the methodological challenges
introduced by new, molecularly targeted agents.
Phase II studies are vital in the development of new drugs. A
first way to improve phase II is to require randomisation of
patients in order to obtain more reliability results. There is no
reason why this cannot be done when phase I has determined the
MTD, beginning with the first patient to enter phase II. Patients
who are not treated with the drug under investigation could
receive the best available care or the treatment they would have
been given if the experimental drug had not been available. Since
phase II patients have advanced disease, already treated with all
the available options, but are usually not terminal, they were very
likely to receive some other treatment, even an off-label one. The
presence of a control group, not for comparative purposes, could
establish whether there is actually any outstanding (unexpected)
activity and help to plan a more rational phase III trial.
A critical aspect is the end point chosen in phase II and here the
present NfG are rather vague. Ideally, it would be important to
establish that the new drug to be considered clinically significant
meaningfully increases survival. Objective responses – morpholo-
gical or biochemical when they are significant – do not always
correlate with clinical improvement. Similarly, disease stabilisation
or PFS are subject to extensive bias, and it is very difficult to accept
any PFS as real if it is not supported by an increase in overall
survival.
No drugs in Europe received marketing approval by EMEA on
the basis of a formal assessment of symptom control or of quality
of life; improvement of these parameters should be more
acceptable than objective tumour response, if the aim of treatment
is palliative.
In any case, unless the new drug dramatically changes the
natural history of a specific tumour, phase III trials should be
compulsory for several reasons. First of all, there is convincing,
and in some cases conclusive evidence that the classification of
solid tumours masks heterogeneous components, causing con-
siderable difference in the prognosis, in terms of survival and
response to treatment (Betensky et al, 2002). Even spectacular
results obtained in some phase II cases may be related to a casual
mix of patients with favourable gene profiles that are not shared by
all patients with the same tumour. The recent results with gefitinib
in lung cancer patients with mutations in the EGFR gene are
striking but only a minority of the lung cancer population may
have this mutation (Lynch et al, 2004; Paez et al, 2004).
Secondly, approving a drug with phase II data gives it a status of
‘active comparator’ in other studies, even if its efficacy has not
been fully established. Thirdly, although the NfG stipulate that
drugs with only phase II studies must undergo further trials, it is
difficult to arrange phase III trials when the efficacy of an
authorised drug is considered well established. It is not infrequent
to hear ethical appeals in order to avoid further trials. Fourth,
under the current legislation, it is extremely difficult to remove
drugs from the market. Therefore, there is a high risk of drugs
Table 4 Primary efficacy end points of the main studies supporting 27
indications
No. %
Overall survival 2 7
TTP/PFS 11 41
Response rate 13 48
Other
a 14
TTP¼time to progression; PFS¼progression-free survival.
aApproval without
empirical data, supported by bibliographic review of nonclinical and clinical data.
Table 3 Design of the main studies supporting 27
a indications
No. %





RCT¼randomised clinical trial; SAT¼single-arm trial; NC-RCT¼noncomparative
RCT.
aIn at least two cases (docetaxel and doxorubicin pegylated), further
comparative RCT were carried out to support preliminary findings.
bApproval
without empirical data, supported by bibliographic review of nonclinical and clinical
data.
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sapproved only with phase II trials being utilised in a number of
patients before confirmative trials are carried out. Last but not
least, ethical considerations are difficult to reconcile with studies
whose aim is essentially commercial.
For these reasons it is suggested that new anticancer drugs be
approved on the basis of phase II studies only in exceptional cases,
when there is really outstanding, unprecedented or unexpected
activity, and that therefore phase III comparative trials should
generally be required.
The current NfG is acceptable for phase III trials except that they
should be not only ‘confirmatory’ but also ‘comparative’. The type
of comparison is also important. The noninferiority design is hard
to accept for at least two reasons: first, anticancer agents are
generally not very effective and therefore it is difficult to make sure
that in a noninferiority trial without a placebo the standard drug
actually shows efficacy; second, this doubt is reinforced by the
limit for noninferiority which is usually relatively generous (15–
20%) and therefore easy to achieve.
Again the preferred end point should be overall survival. It can
be argued that for most tumours a median increase in survival of
1.2 months or so, even if statistically significant, is of questionably
utility because it is so small and there are always many potential
confounding factors. It is evident that a ‘positive risk-benefit’
assessment is difficult in the absence of information about the
patients’ quality of life. If other parameters are used, such as
measures of clinical/therapeutic benefit, they should be supported
by adequate studies to identify a real improvement in quality of life
through validated psychometric and pragmatic scales (Chassany
et al, 2002).
Phase III and phase II studies should be required to include
large proportion of elderly people and, when appropriate, pediatric
trials should be done.
The new NfG should give proper importance to the emerging
differences in outcome due to different genotype profiles (Roberts
and Chabner, 2004). For patients responding well to a treatment
(usually a small proportion) retrospective, preplanned analyses
should be done to see if there is a genotype that identifies responders
or nonresponders. This information would be useful for granting an
indication that takes account of the characteristics of likely
responders, avoiding a broad indication under which many patients
will be treated with no advantage. It is clear that such studies are
unlikely to interest industry because they will shrink the market.
An example of an approval based on molecular requirements is
trastuzumab for advanced breast cancer patients positive for HER-
2 (Vogel et al, 2002), where confirmative phase III studies are
still running. In the meantime, how many patients have been
treated, at a high cost for society, without knowing the real level of
efficacy?
This paper has several limitations. First of all, the evaluation
only pertains to anticancer drugs approved by EMEA following the
centralised procedure and it must be borne in mind that some
important anticancer drugs such as gemcitabine were approved in
Europe during the study period using alternative regulatory
procedures. Secondly, an analysis of the group of agents that were
not approved by EMEA or voluntarily withdrawn by a pharma-
ceutical company would allow a more complete assessment;
unfortunately, this information is not available as it is confidential
and there is no means of tracing any public information on
procedures stopped early. Thirdly, the evaluation is based only on
information for drugs for solid tumours and the findings and
comments cannot be extended to drugs for other cancers. Fourth,
individual drugs have gained their indications with a specific path
in some very restricted forms of cancer and a qualitative
discussion of each example might help to identify critical points
in the development and evaluation process and clarify potential
regulatory and clinical implications; such discussion is beyond the
aims of this paper, but this kind of evaluation is available
elsewhere for some of the drugs assessed (Pignatti et al, 2002).
Finally, the data used in this appraisal came from documents made
available to the public by EPAR, such as the scientific summary; in
general, such documents are not standardised and differ in length,
completeness, level of discussion and amount of technical detail
reported, thus making it difficult to identify and retrieve the
information required for the evaluation; the heterogeneity in
structure, contents and organisation might have introduced a bias.
In conclusion, the present NfG for new anticancer agents need
revising. There should be a very strong obligation for phase III
trials unless we are lucky enough to have found a ‘magic bullet’,
but these are very rare! The design of phase II studies should be
improved to make sure that a positive result points to a real need
for phase III studies. In the light of the EMEA’s attitude, it is
equally important that the NfG are not only revised but also strictly
applied. Of course drugs should be rapidly released for patients
who need them but not at the expense of adequate knowledge
about the real benefit. The pharmaceutical industry’s urgency to
obtain a slice of a flourishing market should be balanced by the
need to provide drugs that meet real need without posing an undue
burden on European national health services.
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